Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles Psoriasis (PSO) is a chronic autoimmune skin condition characterized by rapid and excessive skin cell growth, leading to thick, red, and scaly patches. Conventional topical treatments for PSO are non-specific, have low efficacy, and are associated with adverse effects. Researchers are exploring novel delivery mechanisms, such as nanoparticles (NPs), to improve therapeutic efficacy and reduce toxicity. NPs, due to their small size and large surface area, offer advantages in targeted drug delivery, enhanced drug stability, and controlled release. They can deliver anti-inflammatory, immunosuppressive, or other therapeutic compounds directly to affected skin areas, improving drug penetration and efficacy. NPs can be incorporated into various formulations, including creams, gels, ointments, and sprays, to enhance drug stability, solubility, and bioavailability. These formulations may improve patient compliance and comfort. Psoriasis is a multifactorial condition influenced by genetic, immunologic, and environmental factors. It involves a complex interplay of immune cells, cytokines, and keratinocytes, leading to chronic inflammation. The main types of psoriasis include plaque psoriasis, inverse psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. Conventional topical treatments for PSO include corticosteroids, retinoids, calcineurin inhibitors, vitamin D analogs, and anthralin. However, these treatments face challenges such as poor skin penetration, low bioavailability, and potential side effects. Nanotechnology offers innovative solutions for the topical delivery of anti-psoriatics. Nanoparticles, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and dendrimers, have shown promise in enhancing drug delivery, improving bioavailability, and reducing systemic side effects. Liposomes, for example, can enhance drug solubility, regulate drug distribution, and offer surface modification for target-specific sustained release. SLNs and NLCs have been investigated for their ability to improve drug solubility, cellular uptake, and stability. These nanocarriers can be designed to deliver drugs specifically to the site of disease, minimizing systemic side effects and achieving controlled or sustained release. Despite their potential, the use of nanoparticles in PSO treatment faces challenges such as toxicity, biodegradation, and regulatory approval. Interdisciplinary cooperation and risk evaluation are necessary to address these challenges. Current nanotechnology-based approaches for the topical treatment of psoriasis include liposomes, SLNs, NLCs, and other nanocarriers, which have shown promising results in enhancing drug delivery and therapeutic efficacy. Clinical trials are essential to evaluate the safety and efficacy of these treatments.Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles Psoriasis (PSO) is a chronic autoimmune skin condition characterized by rapid and excessive skin cell growth, leading to thick, red, and scaly patches. Conventional topical treatments for PSO are non-specific, have low efficacy, and are associated with adverse effects. Researchers are exploring novel delivery mechanisms, such as nanoparticles (NPs), to improve therapeutic efficacy and reduce toxicity. NPs, due to their small size and large surface area, offer advantages in targeted drug delivery, enhanced drug stability, and controlled release. They can deliver anti-inflammatory, immunosuppressive, or other therapeutic compounds directly to affected skin areas, improving drug penetration and efficacy. NPs can be incorporated into various formulations, including creams, gels, ointments, and sprays, to enhance drug stability, solubility, and bioavailability. These formulations may improve patient compliance and comfort. Psoriasis is a multifactorial condition influenced by genetic, immunologic, and environmental factors. It involves a complex interplay of immune cells, cytokines, and keratinocytes, leading to chronic inflammation. The main types of psoriasis include plaque psoriasis, inverse psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. Conventional topical treatments for PSO include corticosteroids, retinoids, calcineurin inhibitors, vitamin D analogs, and anthralin. However, these treatments face challenges such as poor skin penetration, low bioavailability, and potential side effects. Nanotechnology offers innovative solutions for the topical delivery of anti-psoriatics. Nanoparticles, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and dendrimers, have shown promise in enhancing drug delivery, improving bioavailability, and reducing systemic side effects. Liposomes, for example, can enhance drug solubility, regulate drug distribution, and offer surface modification for target-specific sustained release. SLNs and NLCs have been investigated for their ability to improve drug solubility, cellular uptake, and stability. These nanocarriers can be designed to deliver drugs specifically to the site of disease, minimizing systemic side effects and achieving controlled or sustained release. Despite their potential, the use of nanoparticles in PSO treatment faces challenges such as toxicity, biodegradation, and regulatory approval. Interdisciplinary cooperation and risk evaluation are necessary to address these challenges. Current nanotechnology-based approaches for the topical treatment of psoriasis include liposomes, SLNs, NLCs, and other nanocarriers, which have shown promising results in enhancing drug delivery and therapeutic efficacy. Clinical trials are essential to evaluate the safety and efficacy of these treatments.